The Impact of Immunosenescence on Ageing

By Melike Belenli Gümüş

September 10, 2024

Introduction

The interplay between infections and chronic health conditions is an important aspect influencing ageing and longevity, intricately linked to economic dynamics. The impact of immunosenescence on ageing is a critical area of study in the healthcare industry. Immunosenescence, which refers to the gradual deterioration of the immune system associated with ageing, plays a crucial role in shaping health outcomes. Inflammageing, which refers to the chronic pro-inflammatory state, also plays an important role in this process. This decline in immune system affects the body’s ability to fight infections and respond to vaccinations. Understanding this process is vital for developing strategies to improve health outcomes for the elderly.

Understanding Immunosenescence

Immunosenescence is characterised by a decline in the functionality of the innate immune system. This includes ineffective pathogen recognition and reduced macrophage activation. Studies show that by age 65, the thymus, which produces T-cells, has lost 60% of its original size. This reduction leads to a decreased diversity in the T-cell repertoire, making the elderly more susceptible to infections.

Chronic Inflammation and Ageing

Recent medical insights highlight the profound influence of individual infection history on health deficits and mortality risks. Chronic inflammation, or inflammageing, is closely linked to immunosenescence. As people age, they often develop a persistent pro-inflammatory state. Consequently, this condition can lead to various chronic diseases, including cardiovascular disease, type 2 diabetes, and Alzheimer’s disease. Furthermore, research indicates that inflammageing is a core mechanism associated with the ageing process.

Impact on Infectious Diseases

The impact of immunosenescence on infectious diseases is profound. Therefore, elderly individuals are more vulnerable to infections like influenza and pneumonia. The COVID-19 pandemic highlighted this vulnerability, with older adults experiencing higher mortality rates. A cytokine storm, a severe immune reaction, can lead to organ failure and death in these individuals.

Modelling Infectious and Chronic Diseases

A recent model developed by Strulik and Grossmann explores the interplay between infectious and chronic diseases. It investigates how health deficits accumulate and affect survival probabilities in detail. Individuals make decisions on consumption, disease prevention, health investments, and savings, subject to budget constraints. The model maximises expected lifetime utility, considering factors like interest rates, mortality rates, and income. It explores how individuals allocate resources to optimise utility over their lifetimes, factoring in the impact of infectious diseases on chronic conditions. The calibration of the model for a typical American man in 2010 highlights the complex relationship between health behaviours, economic factors, and disease prevention strategies. The model provides insights into how individuals make choices regarding protection against diseases, considering factors like age, health status, and economic circumstances.

Strategies for Mitigation

Addressing the impact of immunosenescence on ageing requires a multifaceted approach. The proposed model integrates the interaction between infectious and chronic diseases into the economics of aging, highlighting the role of immunosenescence and inflammation. This approach demonstrates how a history of infections accelerates the development of chronic health deficits, influencing disease severity and mortality with age. By incorporating health spending decisions, the model points out the importance of early and continuous protection against infections to mitigate long-term health impacts. Thus, enhancing vaccination efficacy in the elderly is crucial. Moreover, promoting healthy lifestyles can mitigate chronic inflammation. Research into therapeutic interventions targeting immunosenescence is ongoing, offering hope for improved health outcomes.

Conclusion

Insights into the economic underpinnings of ageing and health outcomes offer a nuanced understanding of the intricate relationship between infections, chronic conditions, and socioeconomic factors. Addressing the decline in immune function among the elderly can enhance their life expectancy and quality of life while also reducing the burden of infectious diseases. Therefore, this study integrates biological mechanisms with economic frameworks to offer a holistic view of the factors influencing health trajectories and longevity trends. Through this approach, valuable insights are provided into the complex dynamics of healthcare economics and ageing.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.